Moody Lynn & Lieberson LLC purchased a new stake in Novartis AG (NYSE:NVS) during the second quarter, Holdings Channel reports. The fund purchased 4,800 shares of the company’s stock, valued at approximately $401,000.

Other large investors have also modified their holdings of the company. Washington Trust Bank boosted its stake in shares of Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock valued at $366,000 after buying an additional 14 shares in the last quarter. North Star Investment Management Corp. boosted its stake in shares of Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after buying an additional 16 shares in the last quarter. Ledyard National Bank boosted its stake in shares of Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock valued at $286,000 after buying an additional 30 shares in the last quarter. Kernodle & Katon Asset Management Group LLC boosted its stake in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares in the last quarter. Finally, First PREMIER Bank boosted its stake in shares of Novartis AG by 2.4% in the first quarter. First PREMIER Bank now owns 2,242 shares of the company’s stock valued at $166,000 after buying an additional 52 shares in the last quarter. Institutional investors own 11.27% of the company’s stock.

Novartis AG (NYSE:NVS) opened at 83.35 on Friday. The company has a market cap of $195.28 billion, a price-to-earnings ratio of 30.43 and a beta of 0.73. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90. The company’s 50-day moving average is $84.17 and its 200 day moving average is $78.68.

Novartis AG (NYSE:NVS) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The company’s quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 EPS. On average, equities analysts predict that Novartis AG will post $4.73 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/moody-lynn-lieberson-llc-takes-position-in-novartis-ag-nvs/1476509.html.

Several equities research analysts have recently commented on the stock. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Thursday, June 22nd. UBS AG reiterated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, May 30th. BidaskClub cut shares of Novartis AG from a “hold” rating to a “sell” rating in a research report on Friday. Leerink Swann reiterated a “market perform” rating and set a $83.00 price target on shares of Novartis AG in a research report on Thursday, June 22nd. Finally, Vetr cut shares of Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 price target for the company. in a research report on Tuesday, April 25th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. Novartis AG presently has a consensus rating of “Hold” and an average price target of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of Novartis AG stock in a transaction dated Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.01% of the company’s stock.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.